JP2016501213A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501213A5
JP2016501213A5 JP2015544557A JP2015544557A JP2016501213A5 JP 2016501213 A5 JP2016501213 A5 JP 2016501213A5 JP 2015544557 A JP2015544557 A JP 2015544557A JP 2015544557 A JP2015544557 A JP 2015544557A JP 2016501213 A5 JP2016501213 A5 JP 2016501213A5
Authority
JP
Japan
Prior art keywords
negative
breast cancer
pharmaceutical composition
subject
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015544557A
Other languages
English (en)
Japanese (ja)
Other versions
JP6466339B2 (ja
JP2016501213A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/002911 external-priority patent/WO2014087230A1/en
Publication of JP2016501213A publication Critical patent/JP2016501213A/ja
Publication of JP2016501213A5 publication Critical patent/JP2016501213A5/ja
Application granted granted Critical
Publication of JP6466339B2 publication Critical patent/JP6466339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015544557A 2012-12-04 2013-12-04 乳がんの処置におけるエリブリンの使用 Active JP6466339B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261733238P 2012-12-04 2012-12-04
US61/733,238 2012-12-04
US201361878204P 2013-09-16 2013-09-16
US61/878,204 2013-09-16
PCT/IB2013/002911 WO2014087230A1 (en) 2012-12-04 2013-12-04 Use of eribulin in the treatment of breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019002177A Division JP6678783B2 (ja) 2012-12-04 2019-01-09 乳がんの処置におけるエリブリンの使用

Publications (3)

Publication Number Publication Date
JP2016501213A JP2016501213A (ja) 2016-01-18
JP2016501213A5 true JP2016501213A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6466339B2 JP6466339B2 (ja) 2019-02-06

Family

ID=50031376

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015544557A Active JP6466339B2 (ja) 2012-12-04 2013-12-04 乳がんの処置におけるエリブリンの使用
JP2019002177A Active JP6678783B2 (ja) 2012-12-04 2019-01-09 乳がんの処置におけるエリブリンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019002177A Active JP6678783B2 (ja) 2012-12-04 2019-01-09 乳がんの処置におけるエリブリンの使用

Country Status (11)

Country Link
US (1) US20140163095A1 (cg-RX-API-DMAC7.html)
EP (1) EP2928464A1 (cg-RX-API-DMAC7.html)
JP (2) JP6466339B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150090921A (cg-RX-API-DMAC7.html)
AU (2) AU2013353745A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012731A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892780A1 (cg-RX-API-DMAC7.html)
IL (1) IL239007B (cg-RX-API-DMAC7.html)
MX (1) MX2015007185A (cg-RX-API-DMAC7.html)
RU (1) RU2689977C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014087230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 b 유사체의 제조를 위한 중간체
PE20120923A1 (es) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013353745A1 (en) * 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
JP6644479B2 (ja) * 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MX386547B (es) * 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
UA126029C2 (uk) * 2017-02-20 2022-08-03 Поліфор Аґ Фармацевтичні комбінації для лікування раку
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
EP3713565A1 (en) * 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
BR112020015909A2 (pt) * 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
CN112262157A (zh) * 2018-03-09 2021-01-22 加利福尼亚大学董事会 化药抗性癌症的组合治疗
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632433C (en) 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 b 유사체의 제조를 위한 중간체
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CA2646156C (en) * 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
EP2578576B9 (en) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
RU2517167C2 (ru) 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
AU2013353745A1 (en) * 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer

Similar Documents

Publication Publication Date Title
RU2015126539A (ru) Применение эрибулина для лечения рака молочной железы
Chae et al. Repurposing metformin for cancer treatment: current clinical studies
Trédan et al. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer
Guion-Dusserre et al. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Velenik et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
Zhang et al. Current landscape of personalized clinical treatments for triple-negative breast cancer
RU2016151303A (ru) Применение эрибулина в лечении рака
Gallagher et al. The pathway from diabetes and obesity to cancer, on the route to targeted therapy
Park et al. Cyclophosphamide, methotrexate, and 5-fluorouracil as palliative treatment for heavily pretreated patients with metastatic breast cancer: a multicenter retrospective analysis
HK1248539A1 (zh) 借助塞里班土单抗的组合治疗
Bisagni et al. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
Park et al. Treatment patterns and outcomes in elderly patients with metastatic breast cancer: a multicenter retrospective study
Noomhorm et al. In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen
Wang et al. Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma
Chen et al. RC48-antibody-drug conjugate in metastatic urothelial carcinoma: A multicenter real-world study in China
EP2999465A1 (en) Specific cancer treatment regimens with ganetespib
Nemunaitis et al. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers
JP5889335B2 (ja) 癌治療用医薬組成物
Piatek et al. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
Melcher et al. 191 DETECT III–a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells
Sikora-Kupis et al. First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
Tsubamoto et al. Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: a Kansai Clinical Oncology Group study (KCOG9812)
US20230406931A1 (en) Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer
Alsina et al. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients: M. Alsina et al.
Ranjan et al. Overview of Traditional Methods of Diagnosis and Treatment for Women-Associated Cancers